CAS: 1233335-78-8; Sofosbuvir Metabolites Gs566500
- 英文名称Sofosbuvir Metabolites Gs566500
- 中文名称索非布韦代谢物GS-566500
- IUPAC名称((((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)-L-alanine
- 其它别名N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-5'-Uridylyl]-L-Alanine; (2S)-2-(((((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1(2H)-yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-yl)Methoxy)(Hydroxy)Phosphoryl)Amino)Propanoic Acid; (2S)-2-(((((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1(2H)-yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-yl)Methoxy)(Hydroxy)Phosphoryl)Amino)Propanoic Acid Ammonium Salt; O-Desisopropyl O-Desphenyl Sofosbuvir Ammonium Salt; (2S)-2-(((((2R,3R,4R,5S)-5-((R)-2,6-Dioxo-1,2,3,6-Tetrahydropyridin-3-yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-yl)Methoxy)(Hydroxy)Phosphoryl)Amino)Propanoic Acid
- CAS编号1233335-78-8
- MFCD编号:MFCD28964036
- FDA UNII编号:8C9Y1F217H
- 分子式:C13H19FN3O9P分子量:411.28
- 产品CID: 336178
- 产品分类分析化学 → 标准品 → 药典标准品和杂质标准品
物理性质
MSDS等安全信息
上下游产品
sofosbuvir合成工艺路线路线简述
- 合成目标产物 Sofosbuvir Metabolites Gs566500 主要起始原料 Psi 7851
- (文献来源)合成步骤主要原料 Psi 7851
📜索罗布维置于水,三乙胺体系中,化学反应 30.0H,以92%的收率获得索非布韦代谢物gs-566500
参考文献: Nucleoside Phosphoramidate Prodrugs[fr] Analogues De Nucléoside
标题: Nucleoside Phosphoramidate Prodrugs[fr] Analogues De Nucléoside
海关参考信息
- 2905122000-异丙醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇
2905399001-1,3-丙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Custodio JM, Chuck SK, Chu H, Cao H, Ma G, Flaherty J, Ling J, Kearney BP. Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide. Pharmacol Res Perspect. 2017 Oct;5(5). doi: 10.1002/prp2.353.
2: Lawitz E, Rodriguez-Torres M, Denning JM, Albanis E, Cornpropst M, Berrey MM, Symonds WT. Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection. Antimicrob Agents Chemother. 2013 Mar;57(3):1209-17. doi: 10.1128/AAC.01263-12. Epub 2012 Dec 21.
3: Denning J, Cornpropst M, Flach SD, Berrey MM, Symonds WT. Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects. Antimicrob Agents Chemother. 2013 Mar;57(3):1201-8. doi: 10.1128/AAC.01262-12. Epub 2012 Dec 21.
📝 需求与反馈
尽可能描述清楚需求与问题信息
